<Suppliers Price>

Reboxetine (mesylate)

Names

[ CAS No. ]:
98769-84-7

[ Name ]:
Reboxetine (mesylate)

[Synonym ]:
Morpholine, 2-[(R)-(2-ethoxyphenoxy)phenylmethyl]-, (2R)-, methanesulfonate (1:1)
REBOXETINE MESYLATE HYDRATE
REBOXETINE,MESYLATE
(2R)-rel-2-[(R)-(2-Ethoxyphenoxy)phenylmethyl]morpholine
EDRONAX
VESTRA
(2R)-2-[(R)-(2-Ethoxyphenoxy)(phenyl)methyl]morpholine methanesulfonate (1:1)
REBOXETINE, MESYLATE
Reboxetine (mesylate)
REBOXETINE MESILATE
Reboxetine hydrate mesylate
Reboxetinemesylate
(±)-(2R*)-2-[(aR*)-a-(o-Ethoxyphenoxy)benzyl]morpholine Methanesulfonate
RAC-N-BENZYL-N-[2-HYDROXYL-2-(4-BENZYLOXY-3-FORMAMIDOPHENYL)-ETHYL]-3-(4-METHOXYPHENYL)-2-PROPYLAMINE-D6
MFCD02184016
REBOXETIN MESYLATE
2-[(2-Ethoxyphenoxy)phenylmethyl]morpholine mesylate

Biological Activity

[Description]:

Reboxetine Mesylate is a norepinephrine reuptake inhibitor use in the treatment of unipolar depression.Target: OthersReboxetine is a drug of the norepinephrine reuptake inhibitor class. Reboxetine dose-dependently and potently inhibits locus coeruleus neuronal firing in rats with ED50 of 191 μg/kg. Reboxetine inhibition of the locus coeruleus neurons is reversible by the α2 antagonist piperoxan (1.5 mg/kg, IV). Reboxetine dose-dependently reverses reserpine-induced blepharospasm and hypothermia in the mouse. Reboxetine is also found to antagonize clonidine-induced hypothermia dose-dependently in mice. Reboxetine reverses reserpine-induced blepharospasm and hypothermia in rats with ED50 of 10 mg/kg and 3 mg/kg (p.o.), respectively [1]. Reboxetine is associated with a markedly lower relapse rate than placebo (22% vs. 56%) and a greater cumulative probability of a maintained response during long-term treatment in patients with recurrent DSM-III-R major depression. Reboxetine effectively prevents recurrence of depressive symptoms following episode resolution [2]. Acute systemic administration of Reboxetine (0.3 mg/kg-20 mg/kg) dose-dependently increases extracellular norepinephrine in the rat frontal cortex while having no effect on extracellular serotonin. Reboxetine (20 mg/kg) also increases extracellular dopamine in the rat frontal cortex. Chronic administration of Reboxetine for 14 days results in elevated basal concentrations of extracellular norepinephrine and dopamine and a greater net increase of extracellular norepinephrine and dopamine, but not serotonin in the rat frontal cortex [3].

[Related Catalog]:

Signaling Pathways >> Others >> Others
Research Areas >> Neurological Disease

[References]

[1]. Wong, E.H., et al., Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry, 2000. 47(9): p. 818-29.

[2]. Versiani, M., et al., Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry, 1999. 60(6): p. 400-6.

[3]. Page, M.E. and I. Lucki, Effects of acute and chronic reboxetine treatment on stress-induced monoamine efflux in the rat frontal cortex. Neuropsychopharmacology, 2002. 27(2): p. 237-47.


[Related Small Molecules]

Captisol | Cyclosporin A | H2DCFDA | 0MPTP hydrochloride | GW4869 | Etomoxir | TD139 | Mitoquinone mesylate | GSK2795039 | JC-1 | BAPTA-AM | AP 20187 | Setanaxib (GKT137831) | D-Luciferin | Crotaline

Chemical & Physical Properties

[ Boiling Point ]:
443.7ºC at 760 mmHg

[ Melting Point ]:
170-171ºC

[ Molecular Formula ]:
C20H27NO6S

[ Molecular Weight ]:
409.496

[ Flash Point ]:
188.2ºC

[ Exact Mass ]:
409.155914

[ PSA ]:
102.47000

[ LogP ]:
4.10740

[ Storage condition ]:
2-8°C

[ Water Solubility ]:
H2O: ~8 mg/mL at ≤60 °C

Safety Information

[ Safety Phrases ]:
S22-S24/25

[ WGK Germany ]:
3

Related Compounds